Measles Seropositivity in HIV-Infected Kenyan Children on Antiretroviral Therapy.

dc.contributor.author	Newman, LP
dc.contributor.author	Njoroge, A
dc.contributor.author	Ben-Youssef, L
dc.contributor.author	Merkel, M
dc.contributor.author	Gatuguta, A
dc.contributor.author	Ton, Q
dc.contributor.author	Obimbo, EM
dc.contributor.author	Wamalwa, D
dc.contributor.author	Lohman-Payne, B
dc.contributor.author	Richardson, BA
dc.contributor.author	Nduati, R
dc.contributor.author	Farquhar, C
dc.date.accessioned	2014-04-03T07:33:20Z
dc.date.available	2014-04-03T07:33:20Z
dc.date.issued	2014-03
dc.identifier.citation	Pediatr Infect Dis J. 2014 Mar 10	en_US
dc.identifier.uri	http://www.ncbi.nlm.nih.gov/pubmed/24618938
dc.identifier.uri	http://hdl.handle.net/11295/65790
dc.description.abstract	This paper describes results from a cross-sectional study among HIV-infected children 15 months to 12 years of age who were receiving antiretroviral therapy. We found a low prevalence of measles IgG seropositivity (45.7%) and identified CD4% ≥ 25 as a predictor. Most HIV-infected children on ART were not measles seropositive and might benefit from revaccination.	en_US
dc.language.iso	en	en_US
dc.publisher	University of Nairobi	en_US
dc.title	Measles Seropositivity in HIV-Infected Kenyan Children on Antiretroviral Therapy.	en_US
dc.type	Working Paper	en_US

Files in this item

Files	Size	Format	View
There are no files associated with this item.